Cohort1: dose level 1_no lymphodepleting
|
Administration route |
intravenous infusion |
Dosage |
3E6 cells |
Donor type |
Autologous |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
No |
Outcome |
1/1(CR) |
References |
DOI:
10.1182/blood-2022-162393
|
|
Cohort2: dose level 1_lymphodepleting
|
Administration route |
intravenous infusion |
Dosage |
3E6 cells |
Donor type |
Autologous |
Pts |
2 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Outcome |
2/2(CR) |
References |
DOI:
10.1182/blood-2022-162393
|
|
Cohort3: dose level 2_lymphodepleting
|
Administration route |
intravenous infusion |
Dosage |
7E6 cells |
Donor type |
Autologous |
Pts |
1 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
DOI:
10.1182/blood-2022-162393
|
|
Cohort4: dose level 3_lymphodepleting
|
Administration route |
intravenous infusion |
Dosage |
3E7 cells |
Donor type |
Autologous |
Pts |
2 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
References |
DOI:
10.1182/blood-2022-162393
|
|